skip to Main Content

Claudin-Specific CAR T Cells Safe, Effective in Advanced Gastric, Pancreatic Adenocarcinoma

Newsfeed image, light gray text on dark gray background
One-third of a small cohort of patients with advanced gastric or pancreatic adenocarcinoma achieved objective responses to treatment with a novel claudin 18.2-specific chimeric antigen receptor T-cell therapy, according to results of a single-arm, phase 1 trial presented at ASCO Annual Meeting.

CAR-CLDN18.2 (CARsgen Therapeutics) targets claudin 18.2, a stomach-specific isoform of claudin-18 that is highly expressed in gastric and pancreatic adenocarcinomas. Read more . . . 


Back To Top